# AZN catalysts: ASTRAZENECA PLC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/azn/catalysts

> ASTRAZENECA PLC (AZN) has 314 upcoming catalysts. The next is the AZD0901 primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ASTRAZENECA PLC |
| Ticker | AZN (NYSE) |
| SEC CIK | 901832 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/azn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 25, 2016 | [Bevespi Aerosphere (formoterol fumarate; glycopyrrolate) FDA approval](https://sec-api.dev/pdufa/formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA208294 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20160425, review_priority STANDARD; sponsor_name ASTRAZENECA; product BEVESPI AEROSPHERE (FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208294%22)) |
| February 27, 2017 | [Qtern (dapagliflozin; saxagliptin hydrochloride) FDA approval](https://sec-api.dev/pdufa/dapagliflozin-saxagliptin) | AZN |  | completed, approved | "NDA209091 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20170227, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product QTERN (DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209091%22)) |
| May 1, 2017 | [Imfinzi® (durvalumab) FDA approval](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170501, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| August 17, 2017 | [LYNPARZA® (olaparib) FDA approval](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170817, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| October 20, 2017 | [Byetta (exenatide synthetic) FDA approval](https://sec-api.dev/pdufa/exenatide-synthetic) | AZN |  | completed, approved | "NDA209210 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20171020, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BYDUREON BCISE (EXENATIDE SYNTHETIC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209210%22)) |
| October 31, 2017 | [Calquence (acalabrutinib) FDA approval](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA210259 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171031, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22)) |
| November 14, 2017 | [Fasenra (benralizumab) FDA approval](https://sec-api.dev/pdufa/benralizumab) | AZN |  | completed, approved | "BLA761070 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171114, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22)) |
| May 18, 2018 | [Lokelma (sodium zirconium cyclosilicate) FDA approval](https://sec-api.dev/pdufa/zirconium-cyclosilicate) | AZN |  | completed, approved | "NDA207078 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180518, review_priority STANDARD; sponsor_name ASTRAZENECA; product LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207078%22)) |
| December 21, 2018 | [Ultomiris (ravulizumab-cwvz) FDA approval](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181221, review_priority PRIORITY; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| May 2, 2019 | [Qternmet Xr (dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride) FDA approval](https://sec-api.dev/pdufa/dapagliflozin-metformin-saxagliptin) | AZN |  | completed, approved | "NDA210874 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20190502, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product QTERNMET XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210874%22)) |
| September 30, 2019 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) complete response letter (CRL)](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212122_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| March 27, 2020 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20200327, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| April 10, 2020 | [Koselugo (selumetinib sulfate) FDA approval](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200410, review_priority PRIORITY; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| April 24, 2020 | [Lokelma (sodium zirconium cyclosilicate) label expansion decision](https://sec-api.dev/pdufa/zirconium-cyclosilicate) | AZN |  | completed, approved | "NDA207078 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20200424, review_priority STANDARD; sponsor_name ASTRAZENECA; product LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207078%22)) |
| May 5, 2020 | [Farxiga (dapagliflozin) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin) | AZN |  | completed, approved | "NDA202293 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20200505, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22)) |
| May 8, 2020 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20200508, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| May 13, 2020 | [Faslodex (fulvestrant) label expansion decision](https://sec-api.dev/pdufa/fulvestrant) | AZN |  | completed, approved | "NDA021344 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20200513, review_priority STANDARD; sponsor_name ASTRAZENECA; product FASLODEX (FULVESTRANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021344%22)) |
| May 19, 2020 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20200519, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| May 23, 2020 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200523, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| May 28, 2020 | [Brilinta (ticagrelor) label expansion decision](https://sec-api.dev/pdufa/ticagrelor) | AZN |  | completed, approved | "NDA022433 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20200528, review_priority STANDARD; sponsor_name ASTRAZENECA; product BRILINTA (TICAGRELOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022433%22)) |
| June 12, 2020 | [Strensiq (asfotase alfa) label expansion decision](https://sec-api.dev/pdufa/asfotase-alfa) | AZN |  | completed, approved | "BLA125513 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20200612, review_priority STANDARD; sponsor_name ALEXION PHARM; product STRENSIQ (ASFOTASE ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125513%22)) |
| July 23, 2020 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) FDA approval](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA212122 ORIG-1: submission_status AP, submission_status_date 20200723, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BREZTRI AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212122%22)) |
| July 28, 2020 | [Faslodex (fulvestrant) label expansion decision](https://sec-api.dev/pdufa/fulvestrant) | AZN |  | completed, approved | "NDA021344 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20200728, review_priority STANDARD; sponsor_name ASTRAZENECA; product FASLODEX (FULVESTRANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021344%22)) |
| October 9, 2020 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20201009, review_priority STANDARD; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| November 5, 2020 | [Brilinta (ticagrelor) label expansion decision](https://sec-api.dev/pdufa/ticagrelor) | AZN |  | completed, approved | "NDA022433 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20201105, review_priority PRIORITY; sponsor_name ASTRAZENECA; product BRILINTA (TICAGRELOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022433%22)) |
| November 18, 2020 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20201118, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| December 7, 2020 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20201207, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| December 9, 2020 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20201209, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| February 19, 2021 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20210219, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| March 11, 2021 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| April 30, 2021 | [Farxiga (dapagliflozin) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin) | AZN |  | completed, approved | "NDA202293 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20210430, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22)) |
| June 7, 2021 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20210607, review_priority PRIORITY; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| July 22, 2021 | [Byetta (exenatide synthetic) label expansion decision](https://sec-api.dev/pdufa/exenatide-synthetic) | AZN |  | completed, approved | "NDA209210 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20210722, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product BYDUREON BCISE (EXENATIDE SYNTHETIC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209210%22)) |
| July 30, 2021 | [Saphnelo (anifrolumab-fnia) FDA approval](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, approved | "BLA761123 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210730, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product SAPHNELO (ANIFROLUMAB-FNIA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761123%22)) |
| November 4, 2021 | [Byetta (exenatide synthetic) label expansion decision](https://sec-api.dev/pdufa/exenatide-synthetic) | AZN |  | completed, approved | "NDA021773 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20211104, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BYETTA (EXENATIDE SYNTHETIC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021773%22)) |
| November 19, 2021 | [Kanuma (sebelipase alfa) label expansion decision](https://sec-api.dev/pdufa/sebelipase-alfa) | AZN |  | completed, approved | "BLA125561 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20211119, review_priority STANDARD; sponsor_name ALEXION PHARM; product KANUMA (SEBELIPASE ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125561%22)) |
| December 17, 2021 | [Tezspire (tezepelumab-ekko) FDA approval](https://sec-api.dev/pdufa/tezepelumab-ekko) | AZN |  | completed, approved | "BLA761224 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211217, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product TEZSPIRE (TEZEPELUMAB-EKKO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761224%22)) |
| January 31, 2022 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| February 3, 2022 | [Xigduo Xr (dapagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin-metformin) | AZN |  | completed, approved | "NDA205649 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220203, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product XIGDUO XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205649%22)) |
| March 11, 2022 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220311, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| April 11, 2022 | [Xigduo Xr (dapagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin-metformin) | AZN |  | completed, approved | "NDA205649 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20220411, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product XIGDUO XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205649%22)) |
| April 27, 2022 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220427, review_priority PRIORITY; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| May 9, 2022 | [Brilinta (ticagrelor) label expansion decision](https://sec-api.dev/pdufa/ticagrelor) | AZN |  | completed, approved | "NDA022433 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20220509, review_priority PRIORITY; sponsor_name ASTRAZENECA; product BRILINTA (TICAGRELOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022433%22)) |
| July 22, 2022 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20220722, review_priority STANDARD; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| August 3, 2022 | [Calquence (acalabrutinib) FDA approval](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA216387 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220803, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216387%22)) |
| August 26, 2022 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20220826, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| September 2, 2022 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20220902, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| October 21, 2022 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20221021, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| October 21, 2022 | [Imjudo (tremelimumab-actl) FDA approval](https://sec-api.dev/pdufa/tremelimumab-actl) | AZN | To treat unresectable hepatocellular carcinoma | completed, approved | "Imjudo \| tremelimumab \| 10/21/2022 \| To treat unresectable hepatocellular carcinomaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| November 10, 2022 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20221110, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| November 10, 2022 | [Imjudo (tremelimumab-actl) FDA approval](https://sec-api.dev/pdufa/tremelimumab-actl) | AZN |  | completed, approved | "BLA761270 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20221110, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product IMJUDO (TREMELIMUMAB-ACTL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761270%22)) |
| January 10, 2023 | [Airsupra (albuterol sulfate; budesonide) FDA approval](https://sec-api.dev/pdufa/albuterol-budesonide) | AZN |  | completed, approved | "NDA214070 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20230110, review_priority STANDARD; sponsor_name ASTRAZENECA; product AIRSUPRA (ALBUTEROL SULFATE; BUDESONIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214070%22)) |
| February 1, 2023 | [Tezspire (tezepelumab-ekko) label expansion decision](https://sec-api.dev/pdufa/tezepelumab-ekko) | AZN |  | completed, approved | "BLA761224 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230201, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product TEZSPIRE (TEZEPELUMAB-EKKO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761224%22)) |
| April 28, 2023 | [Symbicort Aerosphere (budesonide; formoterol fumarate) FDA approval](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN |  | completed, approved | "NDA216579 ORIG-1 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name ASTRAZENECA; product SYMBICORT AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216579%22)) |
| April 28, 2023 | [LYNPARZA® (olaparib) FDA advisory committee meeting](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, positive | "The committee will discuss supplemental new drug application (sNDA) 208558/S–025, for LYNPARZA (olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-28-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04282023)) |
| May 8, 2023 | [Farxiga (dapagliflozin) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin) | AZN |  | completed, approved | "NDA202293 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230508, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22)) |
| May 31, 2023 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230531, review_priority PRIORITY; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| June 8, 2023 | [Beyfortus (nirsevimab-alip) FDA advisory committee meeting](https://sec-api.dev/pdufa/nirsevimab-alip) | AZN |  | completed, positive | "VOTE: Is the overall benefit-risk assessment favorable for the use of nirsevimab for the prevention of RSV lower respiratory tract disease in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season? a. If yes, please discuss your rationale. Page 5 of 6 June 8, 2023 Antimicrobial Drugs Advisory Committee Meeting b. If no, please comment on what additional clinical data are needed to support this indication. Vote Result: Yes: 19 No: 2 Abstain: 0" ([FDA advisory committee calendar](https://www.fda.gov/media/170807/download)) |
| July 17, 2023 | [Beyfortus (nirsevimab-alip) FDA approval](https://sec-api.dev/pdufa/nirsevimab-alip) | AZN | To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release | completed, approved | "Beyfortus \| nirsevimab-alip \| 7/17/2023 \| To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| November 6, 2023 | [LYNPARZA® (olaparib) label expansion decision](https://sec-api.dev/pdufa/olaparib) | AZN |  | completed, approved | "NDA208558 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20231106, review_priority STANDARD; sponsor_name ASTRAZENECA; product LYNPARZA (OLAPARIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208558%22)) |
| November 16, 2023 | [Truqap (capivasertib) FDA approval](https://sec-api.dev/pdufa/capivasertib) | AZN | To treat breast cancer that meets certain disease criteria | completed, approved | "Truqap \| capivasertib \| 11/16/2023 \| To treat breast cancer that meets certain disease criteriaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| December 1, 2023 | [Saphnelo (anifrolumab-fnia) label expansion decision](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, approved | "BLA761123 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20231201, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product SAPHNELO (ANIFROLUMAB-FNIA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761123%22)) |
| December 21, 2023 | [WAINUA (eplontersen) FDA approval](https://sec-api.dev/pdufa/eplontersen) | AZN | To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis | completed, approved | "Wainua \| eplontersen \| 12/21/2023 \| To treat polyneuropathy of hereditary transthyretin-mediated amyloidosisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| January 24, 2024 | [Koselugo (selumetinib sulfate) label expansion decision](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240124, review_priority STANDARD; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| January 31, 2024 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20240131, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| February 16, 2024 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20240216, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| March 22, 2024 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20240322, review_priority STANDARD; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| March 22, 2024 | [Brilinta (ticagrelor) label expansion decision](https://sec-api.dev/pdufa/ticagrelor) | AZN |  | completed, approved | "NDA022433 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20240322, review_priority STANDARD; sponsor_name ASTRAZENECA; product BRILINTA (TICAGRELOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022433%22)) |
| March 29, 2024 | [Voydeya (danicopan) FDA approval](https://sec-api.dev/pdufa/danicopan) | AZN | To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria | completed, approved | "Voydeya \| danicopan \| 3/29/2024 \| To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| April 5, 2024 | [Fasenra (benralizumab) label expansion decision](https://sec-api.dev/pdufa/benralizumab) | AZN |  | completed, approved | "BLA761070 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20240405, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22)) |
| June 12, 2024 | [Farxiga (dapagliflozin) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin) | AZN |  | completed, approved | "NDA202293 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22)) |
| June 12, 2024 | [Xigduo Xr (dapagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin-metformin) | AZN |  | completed, approved | "NDA205649 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product XIGDUO XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205649%22)) |
| June 14, 2024 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20240614, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| July 25, 2024 | [Imfinzi® (durvalumab) FDA advisory committee meeting](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, positive | "The Committee will discuss supplemental biologics license application (sBLA) 761069/S-043, for IMFINZI (durvalumab) injection, submitted by AstraZeneca UK Limited. The proposed indication (use) is IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/updated-agenda-information-july-25-2024-meeting-oncologic-drugs-advisory-committee-meeting)) |
| August 15, 2024 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20240815, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| August 22, 2024 | [Beyfortus (nirsevimab-alip) label expansion decision](https://sec-api.dev/pdufa/nirsevimab-alip) | AZN |  | completed, approved | "BLA761328 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240822, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22)) |
| September 17, 2024 | [Fasenra (benralizumab) label expansion decision](https://sec-api.dev/pdufa/benralizumab) | AZN |  | completed, approved | "BLA761070 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22)) |
| September 25, 2024 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20240925, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| October 11, 2024 | [Kombiglyze Xr (metformin hydrochloride; saxagliptin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/metformin-saxagliptin) | AZN |  | completed, approved | "NDA200678 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20241011, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product KOMBIGLYZE XR (METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA200678%22)) |
| October 11, 2024 | [Onglyza (saxagliptin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/saxagliptin) | AZN |  | completed, approved | "NDA022350 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20241011, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product ONGLYZA (SAXAGLIPTIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022350%22)) |
| December 4, 2024 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20241204, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| December 20, 2024 | [Xigduo Xr (dapagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin-metformin) | AZN |  | completed, approved | "NDA205649 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product XIGDUO XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205649%22)) |
| January 16, 2025 | [Calquence (acalabrutinib) label expansion decision](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA210259 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22)) |
| February 28, 2025 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250228, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| February 28, 2025 | [Soliris (eculizumab) label expansion decision](https://sec-api.dev/pdufa/eculizumab) | AZN |  | completed, approved | "BLA125166 SUPPL-448 (Efficacy): submission_status AP, submission_status_date 20250228, review_priority PRIORITY; sponsor_name ALEXION PHARM; product SOLIRIS (ECULIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125166%22)) |
| March 28, 2025 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| May 2025 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | delayed | "NCT03944772 (Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03944772)) |
| May 7, 2025 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Hypereosinophilic Syndrome | completed | "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04191304)) |
| May 7, 2025 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | Atypical Hemolytic Uremic | completed | "NCT05876351 (Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2025-12-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05876351)) |
| May 9, 2025 | [ASTRAZENECA PLC primary completion](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123)) |
| May 10, 2025 | [CAEL-101 primary completion](https://sec-api.dev/pdufa/cael-101) | AZN | AL Amyloidosis | completed | "NCT04504825 (A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04504825)) |
| May 15, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH | completed | "NCT06578949 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-06-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06578949)) |
| May 21, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06034743 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06034743)) |
| May 22, 2025 | [Part a: zibotentan (dose b) + dapagliflozin primary completion](https://sec-api.dev/pdufa/part-a-zibotentan-dose-b-dapagliflozin) | AZN | Liver Cirrhosis | withdrawn | "NCT05516498 (Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05516498)) |
| May 27, 2025 | [ALXN1720 primary completion](https://sec-api.dev/pdufa/alxn1720) | AZN | Generalized Myasthenia Gravis | completed | "NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05556096)) |
| June 4, 2025 | [Intervention: as mdi primary completion](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924)) |
| June 16, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Muscle- Invasive Bladder Cancer | completed | "NCT05943106 (BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-16 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05943106)) |
| June 30, 2025 | [AZD9833 primary completion](https://sec-api.dev/pdufa/azd9833) | AZN | ER-Positive HER2-Negative Breast Cancer | completed | "NCT04964934 (Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04964934)) |
| July 9, 2025 | [ALXN1850 primary completion](https://sec-api.dev/pdufa/alxn1850) | AZN | Hypophosphatasia | completed | "NCT06079281 (Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079281)) |
| July 14, 2025 | [AZD2693 primary completion](https://sec-api.dev/pdufa/azd2693) | AZN | Nonalcoholic Steatohepatitis | completed | "NCT05809934 (A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05809934)) |
| July 15, 2025 | [AZD3427 primary completion](https://sec-api.dev/pdufa/azd3427) | AZN | Pulmonary Hypertension (World Health Organization Group 2); Heart Failure | completed | "NCT05737940 (A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-15 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05737940)) |
| July 23, 2025 | [Strensiq (asfotase alfa) primary completion](https://sec-api.dev/pdufa/asfotase-alfa) | AZN | Hypophosphatasia | completed | "NCT06079372 (Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079372)) |
| July 24, 2025 | [Nirsevimab primary completion](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049)) |
| July 28, 2025 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT04053634 (Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04053634)) |
| July 28, 2025 | [AZD2389 primary completion](https://sec-api.dev/pdufa/azd2389) | AZN | Liver Fibrosis; Hepatic Cirrhosis | completed | "NCT06750276 (A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750276)) |
| August 12, 2025 | [Bgf mdi hfo 320/14.4/9.6μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-hfo-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | completed | "NCT06075095 (A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075095)) |
| August 17, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Resistant Hypertension | completed | "NCT06168409 (A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-17 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06168409)) |
| August 22, 2025 | [MEDI-546 primary completion](https://sec-api.dev/pdufa/medi-546) | AZN | Systemic Lupus Erythematosus | completed | "NCT04877691 (Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04877691)) |
| August 25, 2025 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | completed | "NCT05374512 (A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374512)) |
| September 10, 2025 | [Koselugo (selumetinib sulfate) label expansion decision](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250910, review_priority PRIORITY; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| September 10, 2025 | [Koselugo (selumetinib; selumetinib sulfate) FDA approval](https://sec-api.dev/pdufa/selumetinib-selumetinib) | AZN |  | completed, approved | "NDA219943 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250910, review_priority PRIORITY; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB; SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219943%22)) |
| September 15, 2025 | [Airsupra (albuterol sulfate; budesonide) label expansion decision](https://sec-api.dev/pdufa/albuterol-budesonide) | AZN |  | completed, approved | "NDA214070 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20250915, review_priority STANDARD; sponsor_name ASTRAZENECA; product AIRSUPRA (ALBUTEROL SULFATE; BUDESONIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214070%22)) |
| September 19, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Thrombotic Microangiopathy | completed | "NCT04543591 (Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04543591)) |
| October 2, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | completed | "NCT05771480 (Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05771480)) |
| October 6, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Advanced or Metastatic Non-Small Cell Lung Cancer | completed | "NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450692)) |
| October 7, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Chronic Kidney Disease; CKD; Cardiac Disease | withdrawn | "NCT05746559 (ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05746559)) |
| October 10, 2025 | [Saphnelo (anifrolumab-fnia) complete response letter (CRL)](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761451_20251010.pdf%22)) |
| October 15, 2025 | [Londamocitinib primary completion](https://sec-api.dev/pdufa/londamocitinib) | AZN | Asthma | completed | "NCT06435273 (Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435273)) |
| October 17, 2025 | [Tezspire (tezepelumab-ekko) label expansion decision](https://sec-api.dev/pdufa/tezepelumab-ekko) | AZN |  | completed, approved | "BLA761224 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product TEZSPIRE (TEZEPELUMAB-EKKO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761224%22)) |
| October 20, 2025 | [Beyfortus (nirsevimab-alip) label expansion decision](https://sec-api.dev/pdufa/nirsevimab-alip) | AZN |  | completed, approved | "BLA761328 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251020, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22)) |
| October 28, 2025 | [AZD4604 primary completion](https://sec-api.dev/pdufa/azd4604) | AZN | Asthma | completed | "NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06020014)) |
| November 4, 2025 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | completed | "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04008706)) |
| November 19, 2025 | [Koselugo (selumetinib sulfate) label expansion decision](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| November 21, 2025 | [Active imp primary completion](https://sec-api.dev/pdufa/active-imp) | AZN | Obesity or Overweight | completed | "NCT06579092 (Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579092)) |
| November 24, 2025 | [Nirsevimab primary completion](https://sec-api.dev/pdufa/nirsevimab) | AZN | Lower Respiratory Tract Infection | completed | "NCT05110261 (Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05110261)) |
| November 24, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06344104 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06344104)) |
| November 25, 2025 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| December 3, 2025 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity or Overweight | completed | "NCT06595238 (A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06595238)) |
| December 8, 2025 | [Soliris (eculizumab) topline data readout](https://sec-api.dev/pdufa/eculizumab) | AZN | Atypical Hemolytic Uremic | completed | "NCT05876351 (Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2025-12-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05876351?tab=results)) |
| December 19, 2025 | [AZD5004 primary completion](https://sec-api.dev/pdufa/azd5004) | AZN | Diabetes Mellitus, Type 2 | completed | "NCT06579105 (Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579105)) |
| December 29, 2025 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | Generalized Myasthenia Gravis (gMG); Refractory gMG | completed | "NCT06764160 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764160)) |
| December 31, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Papillary Renal Cell Carcinoma | completed | "NCT05043090 (Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05043090)) |
| January 5, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Immunoglobulin A Nephropathy; IgAN | completed | "NCT06291376 (Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291376)) |
| January 6, 2026 | [ALXN1850 primary completion](https://sec-api.dev/pdufa/alxn1850) | AZN | Hypophosphatasia | completed | "NCT06079359 (Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-06 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079359)) |
| January 7, 2026 | [Atuliflapon primary completion](https://sec-api.dev/pdufa/atuliflapon) | AZN | Asthma | completed | "NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05251259)) |
| January 12, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | completed | "NCT05925530 (Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925530)) |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05158387 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05158387)) |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05166889 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05166889)) |
| January 22, 2026 | [Treatment a : budesonide, glycopyrronium, and formoterol fumarate primary completion](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT06067828 (A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067828)) |
| February 4, 2026 | [AZD8630 primary completion](https://sec-api.dev/pdufa/azd8630) | AZN | Asthma | completed | "NCT06529419 (A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06529419)) |
| February 10, 2026 | [AZD5462 primary completion](https://sec-api.dev/pdufa/azd5462) | AZN | Chronic Heart Failure | completed | "NCT06299826 (A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299826)) |
| February 19, 2026 | [Calquence (acalabrutinib) label expansion decision](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA210259 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22)) |
| February 23, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT05301842 (Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05301842)) |
| February 26, 2026 | [Tozorakimab 1 primary completion](https://sec-api.dev/pdufa/tozorakimab-1) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05742802 (Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742802)) |
| March 2, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Muscle Invasive Bladder Cancer | completed | "NCT04960709 (Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04960709)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Prostate Cancer | delayed | "NCT05348577 (Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348577)) |
| March 6, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06040086 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06040086)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Triple Negative Breast Neoplasms | delayed | "NCT03997123 (Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03997123)) |
| March 30, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Advanced Hepatocellular Carcinoma | completed | "NCT05883644 (Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05883644)) |
| April 15, 2026 | [WAINUA (eplontersen) label expansion decision](https://sec-api.dev/pdufa/eplontersen) | AZN |  | completed, approved | "NDA217388 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260415, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217388%22)) |
| April 16, 2026 | [Nirsevimab topline data readout](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049?tab=results)) |
| April 17, 2026 | [Bda mdi hfo 160/180 μg primary completion](https://sec-api.dev/pdufa/bda-mdi-hfo-160) | AZN | Asthma | completed | "NCT06502366 (A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06502366)) |
| April 21, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06897748 (A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897748)) |
| April 24, 2026 | [Saphnelo (anifrolumab-fnia) FDA approval](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, approved | "BLA761451 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product SAPHNELO (ANIFROLUMAB-FNIA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761451%22)) |
| April 27, 2026 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) label expansion decision](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA212122 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260427, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BREZTRI AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212122%22)) |
| April 27, 2026 | [Symbicort Aerosphere (budesonide; formoterol fumarate) label expansion decision](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN |  | completed, approved | "NDA216579 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260427, review_priority STANDARD; sponsor_name ASTRAZENECA; product SYMBICORT AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216579%22)) |
| April 30, 2026 | [Etcamah (camizestrant) FDA advisory committee meeting](https://sec-api.dev/pdufa/camizestrant) | AZN |  | completed, negative | "On the morning of April 30, 2026, the Committee will discuss new drug application (NDA) 220359, for camizestrant tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon emergence of ESR1 mutation during first-line endocrine-based therapy, based on an FDA approved test." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026)) |
| April 30, 2026 | [Truqap (capivasertib) FDA advisory committee meeting](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, positive | "On the afternoon of April 30, 2026, the Committee will discuss supplemental new drug application (sNDA) 218197/S-004, for Truqap (capivasertib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with abiraterone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) that is PTEN-deficient as detected by an FDA-approved test." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026)) |
| April 30, 2026 | [AZD7798 primary completion](https://sec-api.dev/pdufa/azd7798) | AZN | Moderate to Severe Crohn's Disease | completed | "NCT06450197 (Phase IIa Study Evaluating AZD7798 in Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06450197)) |
| May 1, 2026 | [Zytiga (abiraterone) FDA advisory committee meeting](https://sec-api.dev/pdufa/abiraterone) | AZN |  | completed | "ODAC overwhelming majority voted that Truqap plus abiraterone and ADT demonstrated a favourable benefit risk profile for patients based on the CAPItello-281 Phase III trial results" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426004226/a7026c.htm)) |
| May 4, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT06606847 (A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06606847)) |
| May 11, 2026 | [AZD9550 primary completion](https://sec-api.dev/pdufa/azd9550) | AZN | Obesity or Overweight | completed | "NCT06862791 (A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06862791)) |
| May 13, 2026 | [Fasenra (benralizumab) label expansion decision](https://sec-api.dev/pdufa/benralizumab) | AZN |  | completed, approved | "BLA761070 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260513, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22)) |
| May 13, 2026 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy | completed | "NCT06194825 (EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194825)) |
| May 13, 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Severe Eosinophilic Asthma | completed | "NCT06465485 (STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465485)) |
| May 15, 2026 | [Baxfendy (baxdrostat) FDA approval](https://sec-api.dev/pdufa/baxdrostat) | AZN | To treat hypertension in combination with other antihypertensive drugs | completed, approved | "Baxfendy \| baxdrostat \| 5/15/2026 \| To treat hypertension in combination with other antihypertensive drugs" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 15, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT03847428 (Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03847428)) |
| May 26, 2026 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Endocrinology; Diabetes, Type II; Obesity | completed | "NCT06851858 (Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06851858)) |
| May 28, 2026 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| May 31, 2026 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer | completed | "NCT06346392 (AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-31 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06346392)) |
| June 1, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | completed | "NCT03682068 (Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03682068)) |
| June 5, 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH | completed | "NCT06578949 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-06-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06578949?tab=results)) |
| June 9, 2026 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | "NCT05048797 (A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-09 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05048797)) |
| June 12, 2026 | [Truqap (capivasertib) label expansion decision](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, approved | "NDA218197 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22)) |
| June 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Neuromyelitis Optica Spectrum Disorder | delayed | "NCT05346354 (Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-06-22 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05346354)) |
| June 24, 2026 | [ALXN2420 primary completion](https://sec-api.dev/pdufa/alxn2420) | AZN | Acromegaly | withdrawn | "NCT07037420 (ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-24 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037420)) |
| June 26, 2026 | [AZD9833 primary completion](https://sec-api.dev/pdufa/azd9833) | AZN | ER-Positive HER2-Negative Breast Cancer | completed | "NCT04711252 (A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04711252)) |
| June 26, 2026 | [ASTRAZENECA PLC topline data readout](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123?tab=results)) |
| June 30, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma (HCC) | completed | "NCT06040099 (A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06040099)) |
| July 2, 2026 | [CAEL-101 topline data readout](https://sec-api.dev/pdufa/cael-101) | AZN | AL Amyloidosis | completed | "NCT04504825 (A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04504825?tab=results)) |
| July 6, 2026 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Carcinoma; Non-Small-Cell Lung | completed | "NCT05261399 (Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261399)) |
| July 6, 2026 | [AZD2389 topline data readout](https://sec-api.dev/pdufa/azd2389) | AZN | Liver Fibrosis; Hepatic Cirrhosis | completed | "NCT06750276 (A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750276?tab=results)) |
| July 7, 2026 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Lung Cancer | completed | "NCT06194448 (To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194448)) |
| July 10, 2026 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Hypereosinophilic Syndrome | completed | "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04191304?tab=results)) |
| July 10, 2026 | [Datopotamab deruxtecan primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-small Cell Lung Cancer | completed | "NCT06564844 (A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564844)) |
| July 14, 2026 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Eosinophilic Esophagitis | completed | "NCT05583227 (Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583227)) |
| July 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Generalized Myasthenia Gravis; gMG | delayed | "NCT05644561 (Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05644561)) |
| July 2026 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer | delayed | "NCT04884360 (D9319C00001- 1L OC Mono Global RCT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04884360)) |
| July 30, 2026 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06034743 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06034743?tab=results)) |
| Aug to Nov 2026 | [Voydeya (danicopan) topline data readout](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05389449)) |
| August 6, 2026 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Resistant Hypertension | completed | "NCT06168409 (A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-17 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06168409?tab=results)) |
| August 10, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05211895)) |
| Aug to Nov 2026 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05211895)) |
| August 10, 2026 | [NEXIUM-20MG primary completion](https://sec-api.dev/pdufa/nexium-20mg) | AZN | Erosive Esophagitis | completed | "NCT05267613 (Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05267613)) |
| Aug to Nov 2026 | [NEXIUM-20MG topline data readout](https://sec-api.dev/pdufa/nexium-20mg) | AZN | Erosive Esophagitis | scheduled | "NCT05267613 (Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05267613)) |
| August 10, 2026 | [AZD7798 primary completion](https://sec-api.dev/pdufa/azd7798) | AZN | Crohn's Disease | completed | "NCT06681324 (Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06681324)) |
| Aug to Nov 2026 | [AZD7798 topline data readout](https://sec-api.dev/pdufa/azd7798) | AZN | Crohn's Disease | scheduled | "NCT06681324 (Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06681324)) |
| August 14, 2026 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer | completed | "NCT07143604 (A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07143604)) |
| Aug to Nov 2026 | [Sonesitatug vedotin topline data readout](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer | scheduled | "NCT07143604 (A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07143604)) |
| August 17, 2026 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Non-small Cell Lung Cancer | completed | "NCT05984277 (A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05984277)) |
| Aug to Nov 2026 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT05984277 (A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05984277)) |
| August 2026 | [Voydeya (danicopan) primary completion](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria | delayed | "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05389449)) |
| August 27, 2026 | [Intervention: as mdi topline data readout](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924?tab=results)) |
| September 1, 2026 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | completed | "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04008706?tab=results)) |
| Sep to Dec 2026 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557838)) |
| Sep to Dec 2026 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | scheduled | "NCT06942910 (A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06942910)) |
| September 3, 2026 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | completed | "NCT07218900 (A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218900)) |
| Sep to Dec 2026 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | scheduled | "NCT07218900 (A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218900)) |
| September 4, 2026 | [Etcamah (camizestrant) FDA approval](https://sec-api.dev/pdufa/camizestrant) | AZN |  | completed, approved | "Etcamah \| camizestrant \| 9/4/2026 \| To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 14, 2026 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20260914, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| September 16, 2026 | [Truqap (capivasertib) label expansion decision](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, approved | "NDA218197 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260916, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22)) |
| September 21, 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Asthma | completed | "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750289)) |
| Sep to Dec 2026 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Asthma | scheduled | "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750289)) |
| September 2026 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | delayed | "NCT06942910 (A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06942910)) |
| September 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | delayed | "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557838)) |
| Oct 2026 to Jan 2027 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Hepatocellular Carcinoma; Biliary Tract Cancer | scheduled | "NCT05775159 (Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05775159)) |
| Oct 2026 to Jan 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008093)) |
| Oct 2026 to Jan 2027 | [Truqap (capivasertib) topline data readout](https://sec-api.dev/pdufa/capivasertib) | AZN | Breast Cancer | scheduled | "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635447)) |
| Oct 2026 to Jan 2027 | [AZD6234 topline data readout](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity/Overweight | scheduled | "NCT07017179 (This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07017179)) |
| October 8, 2026 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) FDA approval](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA220290 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261008, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BREZTRI AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220290%22)) |
| October 21, 2026 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-46 (Efficacy): submission_status AP, submission_status_date 20261021, review_priority PRIORITY; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| October 2026 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity/Overweight | delayed | "NCT07017179 (This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07017179)) |
| October 27, 2026 | [AZD3427 topline data readout](https://sec-api.dev/pdufa/azd3427) | AZN | Pulmonary Hypertension (World Health Organization Group 2); Heart Failure | completed | "NCT05737940 (A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-15 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05737940?tab=results)) |
| October 2026 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Hepatocellular Carcinoma; Biliary Tract Cancer | delayed | "NCT05775159 (Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05775159)) |
| October 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | delayed | "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008093)) |
| October 28, 2026 | [AZD2693 topline data readout](https://sec-api.dev/pdufa/azd2693) | AZN | Nonalcoholic Steatohepatitis | completed | "NCT05809934 (A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05809934?tab=results)) |
| October 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Breast Cancer | delayed | "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635447)) |
| Nov 2026 to Feb 2027 | [AZD0901 topline data readout](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | scheduled | "NCT06219941 (AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06219941)) |
| Nov 2026 to Feb 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| November 2, 2026 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Cutaneous Lupus Erythematosus | completed | "NCT06015737 (A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015737)) |
| Nov 2026 to Feb 2027 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Cutaneous Lupus Erythematosus | scheduled | "NCT06015737 (A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015737)) |
| November 4, 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Thrombotic Microangiopathy | completed | "NCT04543591 (Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04543591?tab=results)) |
| November 2026 | [AZD0901 primary completion](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | scheduled | "NCT06219941 (AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06219941)) |
| November 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| Dec 2026 to Mar 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Cancer | scheduled | "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303532)) |
| Dec 2026 to Mar 2027 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| Dec 2026 to Mar 2027 | [Gefurulimab topline data readout](https://sec-api.dev/pdufa/gefurulimab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607627)) |
| Dec 2026 to Mar 2027 | [Soliris (eculizumab) topline data readout](https://sec-api.dev/pdufa/eculizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorders | scheduled | "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06724809)) |
| Dec 2026 to Mar 2027 | [Baxdrostat/dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222917)) |
| December 2026 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorders | scheduled | "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06724809)) |
| December 2026 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222917)) |
| December 2026 | [Gefurulimab primary completion](https://sec-api.dev/pdufa/gefurulimab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607627)) |
| December 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| December 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Cancer | scheduled | "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303532)) |
| Jan to Apr 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "AIM anticipates topline results in the first quarter of 2027, followed by the analysis of overall survival in the third quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm)) |
| Jan to Apr 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Lung Cancer | scheduled | "NCT05374603 (Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374603)) |
| Jan to Apr 2027 | [Anifrolumab (blinded) topline data readout](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Systemic Sclerosis; Scleroderma | scheduled | "NCT05925803 (Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925803)) |
| Jan to Apr 2027 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417814)) |
| Jan to Apr 2027 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06706817 (A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706817)) |
| Jan to Apr 2027 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000123 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000123)) |
| Jan to Apr 2027 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Heterozygous Familial Hypercholesterolaemia | scheduled | "NCT07000136 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000136)) |
| January 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Heterozygous Familial Hypercholesterolaemia | scheduled | "NCT07000136 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000136)) |
| January 2027 | [Anifrolumab (blinded) primary completion](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Systemic Sclerosis; Scleroderma | scheduled | "NCT05925803 (Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925803)) |
| January 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05221840)) |
| January 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417814)) |
| January 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000123 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000123)) |
| January 2027 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06706817 (A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706817)) |
| January 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Lung Cancer | scheduled | "NCT05374603 (Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374603)) |
| Feb to May 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Lymphoma, Mantle Cell | scheduled | "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02972840)) |
| Feb to May 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04529772)) |
| Feb to May 2027 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Nephritis | scheduled | "NCT05138133 (Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05138133)) |
| Feb to May 2027 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Cancer | scheduled | "NCT05629234 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629234)) |
| Feb to May 2027 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | scheduled | "NCT06087835 (Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06087835)) |
| Feb to May 2027 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | scheduled | "NCT06271837 (A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06271837)) |
| Feb to May 2027 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | scheduled | "NCT06834932 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834932)) |
| Feb to May 2027 | [AZD4144 topline data readout](https://sec-api.dev/pdufa/azd4144) | AZN | Sepsis; Acute Kidney Injury | scheduled | "NCT07215702 (A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215702)) |
| February 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | scheduled | "NCT06271837 (A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06271837)) |
| February 2027 | [AZD4144 primary completion](https://sec-api.dev/pdufa/azd4144) | AZN | Sepsis; Acute Kidney Injury | scheduled | "NCT07215702 (A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215702)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Lymphoma, Mantle Cell | scheduled | "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02972840)) |
| February 2027 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | scheduled | "NCT06087835 (Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06087835)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04529772)) |
| February 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Cancer | scheduled | "NCT05629234 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629234)) |
| February 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | scheduled | "NCT06834932 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834932)) |
| February 2027 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Nephritis | scheduled | "NCT05138133 (Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05138133)) |
| Mar to Jun 2027 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN |  | scheduled | "NCT04482309 (A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04482309)) |
| March 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN |  | scheduled | "NCT04482309 (A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04482309)) |
| Apr to Jul 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | scheduled | "NCT03836261 (Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836261)) |
| Apr to Jul 2027 | [LYNPARZA® (olaparib) topline data readout](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer; Breast Cancer | scheduled | "NCT04421963 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04421963)) |
| Apr to Jul 2027 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Breast Cancer, Early Breast Cancer | scheduled | "NCT05774951 (A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05774951)) |
| Apr to Jul 2027 | [ASTRAZENECA PLC topline data readout](https://sec-api.dev/companies/azn/catalysts) | AZN | Heart Failure and Impaired Kidney Function | scheduled | "NCT06307652 (Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307652)) |
| Apr to Jul 2027 | [AZD5148 topline data readout](https://sec-api.dev/pdufa/azd5148) | AZN | Clostridioides Difficile Infection | scheduled | "NCT07285213 (Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285213)) |
| April 2027 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer; Breast Cancer | scheduled | "NCT04421963 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04421963)) |
| April 2027 | [ASTRAZENECA PLC primary completion](https://sec-api.dev/companies/azn/catalysts) | AZN | Heart Failure and Impaired Kidney Function | scheduled | "NCT06307652 (Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307652)) |
| April 2027 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Breast Cancer, Early Breast Cancer | scheduled | "NCT05774951 (A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05774951)) |
| April 2027 | [AZD5148 primary completion](https://sec-api.dev/pdufa/azd5148) | AZN | Clostridioides Difficile Infection | scheduled | "NCT07285213 (Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285213)) |
| April 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | scheduled | "NCT03836261 (Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836261)) |
| May to Aug 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Gastric Cancer | scheduled | "NCT04379596 (Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04379596)) |
| May to Aug 2027 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Breast Cancer; HER2-positive; Metastatic | scheduled | "NCT04784715 (Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04784715)) |
| May to Aug 2027 | [Voydeya (danicopan) topline data readout](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis | scheduled | "NCT06449001 (Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449001)) |
| May to Aug 2027 | [Laroprovstat/rosuvastatin 1 topline data readout](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) | AZN | Hypercholesterolaemia | scheduled | "NCT07619118 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619118)) |
| May 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Breast Cancer; HER2-positive; Metastatic | scheduled | "NCT04784715 (Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04784715)) |
| May 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Gastric Cancer | scheduled | "NCT04379596 (Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04379596)) |
| May 2027 | [Voydeya (danicopan) primary completion](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis | scheduled | "NCT06449001 (Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449001)) |
| May 2027 | [Laroprovstat/rosuvastatin 1 primary completion](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) | AZN | Hypercholesterolaemia | scheduled | "NCT07619118 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619118)) |
| Jun to Sep 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Esophageal Squamous Cell Carcinoma | scheduled | "NCT04550260 (Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04550260)) |
| Jun to Sep 2027 | [Symbicort Aerosphere (budesonide; formoterol fumarate) topline data readout](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN | Severe Asthma | scheduled | "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06473779)) |
| Jun to Sep 2027 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Colorectal Cancer | scheduled | "NCT06792695 (A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06792695)) |
| Jun to Sep 2027 | [Tozorakimab topline data readout](https://sec-api.dev/pdufa/tozorakimab) | AZN | Asthma | scheduled | "NCT06932263 (Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06932263)) |
| June 2027 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Asthma | scheduled | "NCT06932263 (Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06932263)) |
| June 2027 | [Symbicort Aerosphere (budesonide; formoterol fumarate) primary completion](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN | Severe Asthma | scheduled | "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06473779)) |
| June 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Esophageal Squamous Cell Carcinoma | scheduled | "NCT04550260 (Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04550260)) |
| June 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Colorectal Cancer | scheduled | "NCT06792695 (A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06792695)) |
| Jul to Oct 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | scheduled | "NCT05057494 (A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05057494)) |
| Jul to Oct 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06103864)) |
| Jul to Oct 2027 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06448754 (Volrustomig Priming Regimens Exploratory Phase II Platform Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06448754)) |
| Jul to Oct 2027 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Primary Hyperaldosteronism | scheduled | "NCT07007793 (Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007793)) |
| Jul to Oct 2027 | [ALXN1920 topline data readout](https://sec-api.dev/pdufa/alxn1920) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07157787 (Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-02 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157787)) |
| Jul to Oct 2027 | [Active imp topline data readout](https://sec-api.dev/pdufa/active-imp) | AZN | Liver Fibrosis; Hepatic Cirrhosis | scheduled | "NCT07610837 (Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610837)) |
| Jul to Oct 2027 | [Laroprovstat topline data readout](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolaemia | scheduled | "NCT07619131 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619131)) |
| July 2027 | [ALXN1920 primary completion](https://sec-api.dev/pdufa/alxn1920) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07157787 (Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-02 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157787)) |
| July 2027 | [Active imp primary completion](https://sec-api.dev/pdufa/active-imp) | AZN | Liver Fibrosis; Hepatic Cirrhosis | scheduled | "NCT07610837 (Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610837)) |
| July 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | scheduled | "NCT05057494 (A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05057494)) |
| July 2027 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Primary Hyperaldosteronism | scheduled | "NCT07007793 (Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007793)) |
| July 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06103864)) |
| July 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06448754 (Volrustomig Priming Regimens Exploratory Phase II Platform Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06448754)) |
| July 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolaemia | scheduled | "NCT07619131 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619131)) |
| Aug to Nov 2027 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05120349)) |
| Aug to Nov 2027 | [AZD6793 topline data readout](https://sec-api.dev/pdufa/azd6793) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT07082738 (A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082738)) |
| Aug to Nov 2027 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT07596784 (Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596784)) |
| August 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05120349)) |
| August 2027 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT07596784 (Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596784)) |
| August 2027 | [AZD6793 primary completion](https://sec-api.dev/pdufa/azd6793) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT07082738 (A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082738)) |
| September 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629585)) |
| Sep to Dec 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629585)) |
| Sep to Dec 2027 | [Saruparib topline data readout](https://sec-api.dev/pdufa/saruparib) | AZN | Metastatic Castration-Sensitive Prostate Cancer | scheduled | "NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120491)) |
| September 2027 | [Saruparib primary completion](https://sec-api.dev/pdufa/saruparib) | AZN | Metastatic Castration-Sensitive Prostate Cancer | scheduled | "NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120491)) |
| October 2027 | [Datopotamab deruxtecan (dato-dxd) primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT05489211 (Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05489211)) |
| Oct 2027 to Jan 2028 | [Datopotamab deruxtecan (dato-dxd) topline data readout](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT05489211 (Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05489211)) |
| October 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05801029)) |
| Oct 2027 to Jan 2028 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05801029)) |
| Oct 2027 to Jan 2028 | [Bda mdi topline data readout](https://sec-api.dev/pdufa/bda-mdi) | AZN | Asthma | scheduled | "NCT06307665 (Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307665)) |
| Oct 2027 to Jan 2028 | [Budesonide/albuterol metered dose inhaler, mdi topline data readout](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) | AZN | Asthma | scheduled | "NCT06471257 (A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06471257)) |
| Oct 2027 to Jan 2028 | [ALXN2030 topline data readout](https://sec-api.dev/pdufa/alxn2030) | AZN | Antibody-Mediated Rejection; Kidney Transplantation; Biopsy-proven Histologic Scores | scheduled | "NCT06744647 (Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744647)) |
| Oct 2027 to Jan 2028 | [Azd2373-arm 1 topline data readout](https://sec-api.dev/pdufa/azd2373-arm-1) | AZN | APOL1-Mediated Kidney Disease | scheduled | "NCT06824987 (Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824987)) |
| Oct 2027 to Jan 2028 | [Puxitatug samrotecan topline data readout](https://sec-api.dev/pdufa/puxitatug-samrotecan) | AZN | Endometrial Cancer; Malignant Solid Tumour | scheduled | "NCT07044336 (Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044336)) |
| Oct 2027 to Jan 2028 | [Tarperprumig topline data readout](https://sec-api.dev/pdufa/tarperprumig) | AZN | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | scheduled | "NCT07160608 (Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160608)) |
| Oct 2027 to Jan 2028 | [Laroprovstat topline data readout](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolemia | scheduled | "NCT07930507 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07930507)) |
| October 2027 | [Budesonide/albuterol metered dose inhaler, mdi primary completion](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) | AZN | Asthma | scheduled | "NCT06471257 (A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06471257)) |
| October 2027 | [Azd2373-arm 1 primary completion](https://sec-api.dev/pdufa/azd2373-arm-1) | AZN | APOL1-Mediated Kidney Disease | scheduled | "NCT06824987 (Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824987)) |
| October 2027 | [ALXN2030 primary completion](https://sec-api.dev/pdufa/alxn2030) | AZN | Antibody-Mediated Rejection; Kidney Transplantation; Biopsy-proven Histologic Scores | scheduled | "NCT06744647 (Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744647)) |
| October 2027 | [Tarperprumig primary completion](https://sec-api.dev/pdufa/tarperprumig) | AZN | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | scheduled | "NCT07160608 (Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160608)) |
| October 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolemia | scheduled | "NCT07930507 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-10-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07930507)) |
| October 2027 | [Bda mdi primary completion](https://sec-api.dev/pdufa/bda-mdi) | AZN | Asthma | scheduled | "NCT06307665 (Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307665)) |
| October 2027 | [Puxitatug samrotecan primary completion](https://sec-api.dev/pdufa/puxitatug-samrotecan) | AZN | Endometrial Cancer; Malignant Solid Tumour | scheduled | "NCT07044336 (Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044336)) |
| November 2027 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Locally Advanced (Inoperable) or Metastatic Breast Cancer | scheduled | "NCT04862663 (Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862663)) |
| Nov 2027 to Feb 2028 | [Truqap (capivasertib) topline data readout](https://sec-api.dev/pdufa/capivasertib) | AZN | Locally Advanced (Inoperable) or Metastatic Breast Cancer | scheduled | "NCT04862663 (Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862663)) |
| Nov 2027 to Feb 2028 | [Tozorakimab topline data readout](https://sec-api.dev/pdufa/tozorakimab) | AZN | Viral Lung Infection and Acute Respiratory Failure | scheduled | "NCT05624450 (Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624450)) |
| November 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | NSCLC | scheduled | "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05687266)) |
| Nov 2027 to Feb 2028 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | NSCLC | scheduled | "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05687266)) |
| Nov 2027 to Feb 2028 | [AZD0901 topline data readout](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer | scheduled | "NCT05702229 (Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702229)) |
| Nov 2027 to Feb 2028 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06079671 (Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079671)) |
| Nov 2027 to Feb 2028 | [Faslodex (fulvestrant) topline data readout](https://sec-api.dev/pdufa/fulvestrant) | AZN | Locally Advanced or Metastatic Breast Cancer | scheduled | "NCT06764186 (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764186)) |
| Nov 2027 to Feb 2028 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Delayed Graft Function; DGF; Kidney Transplant | scheduled | "NCT06830798 (Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830798)) |
| Nov 2027 to Feb 2028 | [Sonesitatug vedotin topline data readout](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastroesophageal Adenocarcinoma | scheduled | "NCT07069712 (A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069712)) |
| Nov 2027 to Feb 2028 | [AZD1163 topline data readout](https://sec-api.dev/pdufa/azd1163) | AZN | Rheumatoid Arthritis | scheduled | "NCT07276581 (A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276581)) |
| November 2027 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Viral Lung Infection and Acute Respiratory Failure | scheduled | "NCT05624450 (Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624450)) |
| November 2027 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastroesophageal Adenocarcinoma | scheduled | "NCT07069712 (A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069712)) |
| November 2027 | [AZD1163 primary completion](https://sec-api.dev/pdufa/azd1163) | AZN | Rheumatoid Arthritis | scheduled | "NCT07276581 (A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276581)) |
| November 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06079671 (Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079671)) |
| November 2027 | [AZD0901 primary completion](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer | scheduled | "NCT05702229 (Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702229)) |
| November 2027 | [Faslodex (fulvestrant) primary completion](https://sec-api.dev/pdufa/fulvestrant) | AZN | Locally Advanced or Metastatic Breast Cancer | scheduled | "NCT06764186 (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764186)) |
| November 2027 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Delayed Graft Function; DGF; Kidney Transplant | scheduled | "NCT06830798 (Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830798)) |
| Dec 2027 to Mar 2028 | [ALXN2220 topline data readout](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy | scheduled | "NCT06183931 (Study of ALXN2220 Versus Placebo in Adults With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06183931)) |
| Dec 2027 to Mar 2028 | [Bgf mdi 320/14.4/9.6 μg topline data readout](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT06283966 (A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06283966)) |
| Dec 2027 to Mar 2028 | [Acalabrutinib + r-chop standard of care topline data readout](https://sec-api.dev/pdufa/acalabrutinib-r-chop-standard-of-care) | AZN | Mantle-cell Lymphoma | scheduled | "NCT07029737 (A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029737)) |
| Dec 2027 to Mar 2028 | [AZD0292 topline data readout](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07088926 (A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088926)) |
| Dec 2027 to Mar 2028 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT07427394 (Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07427394)) |
| December 2027 | [Bgf mdi 320/14.4/9.6 μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT06283966 (A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06283966)) |
| December 2027 | [ALXN2220 primary completion](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy | scheduled | "NCT06183931 (Study of ALXN2220 Versus Placebo in Adults With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06183931)) |
| December 2027 | [AZD0292 primary completion](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07088926 (A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088926)) |
| December 2027 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT07427394 (Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07427394)) |
| December 2027 | [Acalabrutinib + r-chop standard of care primary completion](https://sec-api.dev/pdufa/acalabrutinib-r-chop-standard-of-care) | AZN | Mantle-cell Lymphoma | scheduled | "NCT07029737 (A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029737)) |
| Jan to Apr 2028 | [Anifrolumab (blinded) topline data readout](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Polymyositis, Dermatomyositis | scheduled | "NCT06455449 (A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455449)) |
| Jan to Apr 2028 | [AZD0292 topline data readout](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07774403 (A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07774403)) |
| January 2028 | [Anifrolumab (blinded) primary completion](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Polymyositis, Dermatomyositis | scheduled | "NCT06455449 (A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455449)) |
| January 2028 | [AZD0292 primary completion](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07774403 (A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07774403)) |
| Feb to May 2028 | [Baxdrostat/dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT06268873 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268873)) |
| Feb to May 2028 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) | scheduled | "NCT06512883 (A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06512883)) |
| Feb to May 2028 | [Dato-dxd topline data readout](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | scheduled | "NCT07205822 (A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07205822)) |
| Feb to May 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Severe Asthma | scheduled | "NCT07363642 (Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363642)) |
| Feb to May 2028 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension | scheduled | "NCT07686120 (A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686120)) |
| February 2028 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | scheduled | "NCT07205822 (A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07205822)) |
| February 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Severe Asthma | scheduled | "NCT07363642 (Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363642)) |
| February 2028 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension | scheduled | "NCT07686120 (A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686120)) |
| February 2028 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) | scheduled | "NCT06512883 (A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06512883)) |
| February 2028 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT06268873 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268873)) |
| Mar to Jun 2028 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350097)) |
| Mar to Jun 2028 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06943833 (A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943833)) |
| March 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07520162 (A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07520162)) |
| Mar to Jun 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07520162 (A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07520162)) |
| March 2028 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06943833 (A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943833)) |
| March 2028 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350097)) |
| Apr to Jul 2028 | [Surovatamig topline data readout](https://sec-api.dev/pdufa/surovatamig) | AZN | B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL) | scheduled | "NCT06526793 (Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06526793)) |
| Apr to Jul 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Obesity; Overweight | scheduled | "NCT07775404 (A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775404)) |
| April 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Obesity; Overweight | scheduled | "NCT07775404 (A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775404)) |
| April 2028 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL) | scheduled | "NCT06526793 (Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06526793)) |
| May to Aug 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Asthma | scheduled | "NCT06023589 (A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06023589)) |
| May to Aug 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662213 (A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662213)) |
| May to Aug 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07664553 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07664553)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662213 (A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662213)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07664553 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07664553)) |
| May 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Asthma | scheduled | "NCT06023589 (A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06023589)) |
| Jun to Sep 2028 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06467357)) |
| Jun to Sep 2028 | [AZD0120 topline data readout](https://sec-api.dev/pdufa/azd0120) | AZN | Relapsed Refractory Multiple Myeloma | scheduled | "NCT07391657 (A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07391657)) |
| June 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06467357)) |
| June 2028 | [AZD0120 primary completion](https://sec-api.dev/pdufa/azd0120) | AZN | Relapsed Refractory Multiple Myeloma | scheduled | "NCT07391657 (A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07391657)) |
| Jul to Oct 2028 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662044)) |
| Jul to Oct 2028 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662109)) |
| Jul to Oct 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease | scheduled | "NCT07662135 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662135)) |
| Jul to Oct 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Weight Management | scheduled | "NCT07667803 (A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07667803)) |
| July 2028 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662109)) |
| July 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease | scheduled | "NCT07662135 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662135)) |
| July 2028 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662044)) |
| July 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Weight Management | scheduled | "NCT07667803 (A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07667803)) |
| Aug to Nov 2028 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate | scheduled | "NCT06960577 (Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960577)) |
| Aug to Nov 2028 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Erythematosus, Systemic | scheduled | "NCT07751848 (A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07751848)) |
| Aug to Nov 2028 | [Lenbelintide topline data readout](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2 | scheduled | "NCT07776509 (A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07776509)) |
| Aug to Nov 2028 | [Lenbelintide topline data readout](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07784270 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784270)) |
| Aug to Nov 2028 | [Lenbelintide topline data readout](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight | scheduled | "NCT07784725 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784725)) |
| August 2028 | [Lenbelintide primary completion](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2 | scheduled | "NCT07776509 (A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07776509)) |
| August 2028 | [Lenbelintide primary completion](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07784270 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784270)) |
| August 2028 | [Lenbelintide primary completion](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight | scheduled | "NCT07784725 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784725)) |
| August 2028 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Erythematosus, Systemic | scheduled | "NCT07751848 (A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07751848)) |
| August 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate | scheduled | "NCT06960577 (Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960577)) |
| Sep to Dec 2028 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT07557420 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07557420)) |
| Sep to Dec 2028 | [Azd8965 low dose topline data readout](https://sec-api.dev/pdufa/azd8965) | AZN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07652658 (A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652658)) |
| Sep to Dec 2028 | [Torvutatug samrotecan topline data readout](https://sec-api.dev/pdufa/torvutatug-samrotecan) | AZN |  | scheduled | "NCT07816666 (Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816666)) |
| Sep to Dec 2028 | [AZD6234 topline data readout](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity; Overweight; Type 2 Diabetes Mellitus | scheduled | "NCT07922330 (A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07922330)) |
| September 2028 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity; Overweight; Type 2 Diabetes Mellitus | scheduled | "NCT07922330 (A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07922330)) |
| September 2028 | [Azd8965 low dose primary completion](https://sec-api.dev/pdufa/azd8965) | AZN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07652658 (A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652658)) |
| September 2028 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT07557420 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07557420)) |
| September 2028 | [Torvutatug samrotecan primary completion](https://sec-api.dev/pdufa/torvutatug-samrotecan) | AZN |  | scheduled | "NCT07816666 (Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816666)) |
| Oct 2028 to Jan 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03833154)) |
| Oct 2028 to Jan 2029 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT05835310 (An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05835310)) |
| Oct 2028 to Jan 2029 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Mantle Cell Lymphoma (MCL) | scheduled | "NCT05951959 (A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05951959)) |
| Oct 2028 to Jan 2029 | [Surovatamig topline data readout](https://sec-api.dev/pdufa/surovatamig) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07571746 (A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571746)) |
| October 2028 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT05835310 (An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05835310)) |
| October 2028 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07571746 (A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571746)) |
| October 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03833154)) |
| October 2028 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Mantle Cell Lymphoma (MCL) | scheduled | "NCT05951959 (A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05951959)) |
| Nov 2028 to Feb 2029 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Unresectable Pleural Mesothelioma | scheduled | "NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097728)) |
| Nov 2028 to Feb 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112379)) |
| Nov 2028 to Feb 2029 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN |  | scheduled | "NCT06535607 (Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06535607)) |
| Nov 2028 to Feb 2029 | [Durvalumab + chemotherapy phase topline data readout](https://sec-api.dev/pdufa/durvalumab-chemotherapy-phase) | AZN | Advanced or Recurrent Endometrial Cancer | scheduled | "NCT06746116 (A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06746116)) |
| Nov 2028 to Feb 2029 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | IgAN; IgAVN; Immunoglobulin A Nephropathy | scheduled | "NCT07024563 (Study of Ravulizumab in Pediatric Participants With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-29 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024563)) |
| Nov 2028 to Feb 2029 | [AZD5335 topline data readout](https://sec-api.dev/pdufa/azd5335) | AZN | Epithelial Ovarian Cancer | scheduled | "NCT07218809 (AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218809)) |
| Nov 2028 to Feb 2029 | [AZD0120 topline data readout](https://sec-api.dev/pdufa/azd0120) | AZN | Newly Diagnosed Multiple Myeloma (NDMM) | scheduled | "NCT07735637 (A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07735637)) |
| November 2028 | [AZD0120 primary completion](https://sec-api.dev/pdufa/azd0120) | AZN | Newly Diagnosed Multiple Myeloma (NDMM) | scheduled | "NCT07735637 (A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07735637)) |
| November 2028 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Unresectable Pleural Mesothelioma | scheduled | "NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097728)) |
| November 2028 | [AZD5335 primary completion](https://sec-api.dev/pdufa/azd5335) | AZN | Epithelial Ovarian Cancer | scheduled | "NCT07218809 (AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218809)) |
| November 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112379)) |
| November 2028 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | IgAN; IgAVN; Immunoglobulin A Nephropathy | scheduled | "NCT07024563 (Study of Ravulizumab in Pediatric Participants With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-29 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024563)) |
| November 2028 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN |  | scheduled | "NCT06535607 (Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06535607)) |
| November 2028 | [Durvalumab + chemotherapy phase primary completion](https://sec-api.dev/pdufa/durvalumab-chemotherapy-phase) | AZN | Advanced or Recurrent Endometrial Cancer | scheduled | "NCT06746116 (A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06746116)) |
| Dec 2028 to Mar 2029 | [Tozorakimab dose regimen 1 topline data readout](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) | AZN | Chronic Obstructive Pulmonary Disease; COPD | scheduled | "NCT07566195 (Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07566195)) |
| December 2028 | [Tozorakimab dose regimen 1 primary completion](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) | AZN | Chronic Obstructive Pulmonary Disease; COPD | scheduled | "NCT07566195 (Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07566195)) |
| Jan to Apr 2029 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Biliary Tract Cancer | scheduled | "NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109779)) |
| Jan to Apr 2029 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Endometrial Cancer | scheduled | "NCT06989112 (DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-19 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989112)) |
| Jan to Apr 2029 | [Datopotamab deruxtecan (dato-dxd) topline data readout](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07291037 (Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07291037)) |
| Jan to Apr 2029 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07430306 (A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430306)) |
| Jan to Apr 2029 | [AZD0120 topline data readout](https://sec-api.dev/pdufa/azd0120) | AZN | Newly Diagnosed Multiple Myeloma | scheduled | "NCT07764978 (Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07764978)) |
| January 2029 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Biliary Tract Cancer | scheduled | "NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109779)) |
| January 2029 | [AZD0120 primary completion](https://sec-api.dev/pdufa/azd0120) | AZN | Newly Diagnosed Multiple Myeloma | scheduled | "NCT07764978 (Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07764978)) |
| January 2029 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Endometrial Cancer | scheduled | "NCT06989112 (DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-19 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989112)) |
| January 2029 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07430306 (A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430306)) |
| January 2029 | [Datopotamab deruxtecan (dato-dxd) primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07291037 (Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07291037)) |
| Feb to May 2029 | [WAINUA (eplontersen) topline data readout](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07608354 (A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07608354)) |
| Feb to May 2029 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | ER-Positive HER2-Negative Breast Cancer | scheduled | "NCT07647328 (A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07647328)) |
| February 2029 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07608354 (A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07608354)) |
| February 2029 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | ER-Positive HER2-Negative Breast Cancer | scheduled | "NCT07647328 (A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07647328)) |
| Mar to Jun 2029 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06878261 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878261)) |
| Mar to Jun 2029 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06883305 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06883305)) |
| March 2029 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06878261 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878261)) |
| March 2029 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06883305 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06883305)) |
| Apr to Jul 2029 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952024)) |
| Apr to Jul 2029 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | scheduled | "NCT06764875 (A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764875)) |
| Apr to Jul 2029 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT07098338 (A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07098338)) |
| April 2029 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT07098338 (A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07098338)) |
| April 2029 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952024)) |
| April 2029 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | scheduled | "NCT06764875 (A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764875)) |
| May 2029 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | scheduled | "NCT07024706 (MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024706)) |
| May to Aug 2029 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | scheduled | "NCT07024706 (MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024706)) |
| May to Aug 2029 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Lung Cancer | scheduled | "NCT07295821 (Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07295821)) |
| May to Aug 2029 | [Gp mdi topline data readout](https://sec-api.dev/pdufa/gp-mdi) | AZN | Asthma | scheduled | "NCT07525375 (A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525375)) |
| May 2029 | [Gp mdi primary completion](https://sec-api.dev/pdufa/gp-mdi) | AZN | Asthma | scheduled | "NCT07525375 (A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525375)) |
| May 2029 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Lung Cancer | scheduled | "NCT07295821 (Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07295821)) |
| Jun to Sep 2029 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05546866)) |
| Jun to Sep 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Small Cell Lung Carcinoma | scheduled | "NCT06992609 (Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06992609)) |
| Jun to Sep 2029 | [Xofigo topline data readout](https://sec-api.dev/pdufa/xofigo) | AZN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07611110 (AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07611110)) |
| June 2029 | [Xofigo primary completion](https://sec-api.dev/pdufa/xofigo) | AZN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07611110 (AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07611110)) |
| June 2029 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05546866)) |
| June 2029 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Small Cell Lung Carcinoma | scheduled | "NCT06992609 (Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06992609)) |
| Jul to Oct 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221253)) |
| Jul to Oct 2029 | [Bff mdi topline data readout](https://sec-api.dev/pdufa/bff-mdi) | AZN | Asthma | scheduled | "NCT07934420 (An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934420)) |
| July 2029 | [Bff mdi primary completion](https://sec-api.dev/pdufa/bff-mdi) | AZN | Asthma | scheduled | "NCT07934420 (An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934420)) |
| July 2029 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221253)) |
| Aug to Nov 2029 | [Sonesitatug vedotin topline data readout](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer | scheduled | "NCT07431281 (Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431281)) |
| August 2029 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer | scheduled | "NCT07431281 (Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431281)) |
| Sep to Dec 2029 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN |  | scheduled | "NCT07761117 (A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07761117)) |
| September 2029 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN |  | scheduled | "NCT07761117 (A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07761117)) |
| Oct 2029 to Jan 2030 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000357 (A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000357)) |
| October 2029 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000357 (A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000357)) |
| Nov 2029 to Feb 2030 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Stage II-IIIB Non-small Cell Lung Carcinoma | scheduled | "NCT05526755 (A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526755)) |
| November 2029 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Gastric; Esophagogastric Junction | scheduled | "NCT07877818 (A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07877818)) |
| Nov 2029 to Feb 2030 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Gastric; Esophagogastric Junction | scheduled | "NCT07877818 (A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07877818)) |
| November 2029 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Stage II-IIIB Non-small Cell Lung Carcinoma | scheduled | "NCT05526755 (A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526755)) |
| Dec 2029 to Mar 2030 | [Datopotamab deruxtecan topline data readout](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT06357533 (Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06357533)) |
| Dec 2029 to Mar 2030 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT06380751 (Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380751)) |
| Dec 2029 to Mar 2030 | [Baxdrostat and dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) | AZN | Heart Failure | scheduled | "NCT06677060 (Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06677060)) |
| Dec 2029 to Mar 2030 | [Baxdrostat/dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT06742723 (A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742723)) |
| Dec 2029 to Mar 2030 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN |  | scheduled | "NCT07444567 (Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444567)) |
| December 2029 | [Baxdrostat and dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) | AZN | Heart Failure | scheduled | "NCT06677060 (Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06677060)) |
| December 2029 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT06380751 (Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380751)) |
| December 2029 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT06742723 (A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742723)) |
| December 2029 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN |  | scheduled | "NCT07444567 (Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444567)) |
| December 2029 | [Datopotamab deruxtecan primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT06357533 (Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06357533)) |
| Jan to Apr 2030 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Carcinoma, Non-Small Cell Lung | scheduled | "NCT06868277 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868277)) |
| January 2030 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Carcinoma, Non-Small Cell Lung | scheduled | "NCT06868277 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868277)) |
| Feb to May 2030 | [Sodium zirconium cyclosilicate (szc) reduced dose level topline data readout](https://sec-api.dev/pdufa/zirconium-cyclosilicate-szc-reduced) | AZN | Hyperkalaemia | scheduled | "NCT03813407 (An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03813407)) |
| February 2030 | [Sodium zirconium cyclosilicate (szc) reduced dose level primary completion](https://sec-api.dev/pdufa/zirconium-cyclosilicate-szc-reduced) | AZN | Hyperkalaemia | scheduled | "NCT03813407 (An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03813407)) |
| Mar to Jun 2030 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Breast Cancer, Early Breast Cancer | scheduled | "NCT05952557 (An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952557)) |
| Mar to Jun 2030 | [Tremelimumab topline data readout](https://sec-api.dev/pdufa/tremelimumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT06921785 (Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921785)) |
| March 2030 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Breast Cancer, Early Breast Cancer | scheduled | "NCT05952557 (An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952557)) |
| March 2030 | [Tremelimumab primary completion](https://sec-api.dev/pdufa/tremelimumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT06921785 (Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921785)) |
| Apr to Jul 2030 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06129864 (A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06129864)) |
| April 2030 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06129864 (A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06129864)) |
| May to Aug 2030 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05061550)) |
| May 2030 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05061550)) |
| Jun to Sep 2030 | [AZD0486 topline data readout](https://sec-api.dev/pdufa/azd0486) | AZN | Large B-cell Lymphoma | scheduled | "NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215585)) |
| Jun to Sep 2030 | [Torvutatug samrotecan topline data readout](https://sec-api.dev/pdufa/torvutatug-samrotecan) | AZN | Epithelial Ovarian Cancer | scheduled | "NCT07851025 (Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851025)) |
| June 2030 | [AZD0486 primary completion](https://sec-api.dev/pdufa/azd0486) | AZN | Large B-cell Lymphoma | scheduled | "NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215585)) |
| June 2030 | [Torvutatug samrotecan primary completion](https://sec-api.dev/pdufa/torvutatug-samrotecan) | AZN | Epithelial Ovarian Cancer | scheduled | "NCT07851025 (Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851025)) |
| July 2030 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06692738 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06692738)) |
| Jul to Oct 2030 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06692738 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06692738)) |
| July 2030 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Renal Insufficiency, Chronic | scheduled | "NCT07624305 (A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07624305)) |
| Jul to Oct 2030 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Renal Insufficiency, Chronic | scheduled | "NCT07624305 (A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07624305)) |
| Jul to Oct 2030 | [ALXN2220 topline data readout](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07789483 (An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07789483)) |
| July 2030 | [ALXN2220 primary completion](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07789483 (An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07789483)) |
| Sep to Dec 2030 | [Anifrolumab + apfs topline data readout](https://sec-api.dev/pdufa/anifrolumab-apfs) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07630714 (A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07630714)) |
| Sep to Dec 2030 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | High-risk Muscle Invasive Urothelial Carcinoma | scheduled | "NCT07720284 (An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07720284)) |
| Sep to Dec 2030 | [Surovatamig topline data readout](https://sec-api.dev/pdufa/surovatamig) | AZN | Large B-cell Lymphoma | scheduled | "NCT07911553 (A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911553)) |
| September 2030 | [Anifrolumab + apfs primary completion](https://sec-api.dev/pdufa/anifrolumab-apfs) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07630714 (A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07630714)) |
| September 2030 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | Large B-cell Lymphoma | scheduled | "NCT07911553 (A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911553)) |
| September 2030 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | High-risk Muscle Invasive Urothelial Carcinoma | scheduled | "NCT07720284 (An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07720284)) |
| Oct 2030 to Jan 2031 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Chronic Kidney Disease | scheduled | "NCT07753993 (A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753993)) |
| October 2030 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Chronic Kidney Disease | scheduled | "NCT07753993 (A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753993)) |

## Drugs

- [Zytiga (abiraterone)](https://sec-api.dev/pdufa/abiraterone): 
- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib): Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Lymphoma, Mantle Cell
- [Acalabrutinib + r-chop standard of care](https://sec-api.dev/pdufa/acalabrutinib-r-chop-standard-of-care): Mantle-cell Lymphoma
- [Active imp](https://sec-api.dev/pdufa/active-imp): Liver Fibrosis, Obesity or Overweight
- [Airsupra (albuterol sulfate; budesonide)](https://sec-api.dev/pdufa/albuterol-budesonide): 
- [ALXN1720](https://sec-api.dev/pdufa/alxn1720): Generalized Myasthenia Gravis
- [ALXN1850](https://sec-api.dev/pdufa/alxn1850): Hypophosphatasia
- [ALXN1920](https://sec-api.dev/pdufa/alxn1920): Primary Membranous Nephropathy
- [ALXN2030](https://sec-api.dev/pdufa/alxn2030): Antibody-Mediated Rejection
- [ALXN2220](https://sec-api.dev/pdufa/alxn2220): Transthyretin Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- [ALXN2420](https://sec-api.dev/pdufa/alxn2420): Acromegaly
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab): Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Erythematosus, Systemic, Cutaneous Lupus Erythematosus
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs): Systemic Lupus Erythematosus
- [Anifrolumab (blinded)](https://sec-api.dev/pdufa/anifrolumab-blinded): Polymyositis, Dermatomyositis, Systemic Sclerosis
- [Saphnelo (anifrolumab-fnia)](https://sec-api.dev/pdufa/anifrolumab-fnia): 
- [Strensiq (asfotase alfa)](https://sec-api.dev/pdufa/asfotase-alfa): Hypophosphatasia
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon): Asthma
- [AZD0120](https://sec-api.dev/pdufa/azd0120): Relapsed Refractory Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Newly Diagnosed Multiple Myeloma
- [AZD0292](https://sec-api.dev/pdufa/azd0292): Bronchiectasis With Pseudomonas Aeruginosa Colonization
- [AZD0486](https://sec-api.dev/pdufa/azd0486): Large B-cell Lymphoma
- [AZD0780](https://sec-api.dev/pdufa/azd0780): Dyslipidaemia, Cardiovascular Disease, Heterozygous Familial Hypercholesterolaemia
- [AZD0901](https://sec-api.dev/pdufa/azd0901): Gastric Cancer
- [AZD1163](https://sec-api.dev/pdufa/azd1163): Rheumatoid Arthritis
- [Azd2373-arm 1](https://sec-api.dev/pdufa/azd2373-arm-1): APOL1-Mediated Kidney Disease
- [AZD2389](https://sec-api.dev/pdufa/azd2389): Liver Fibrosis
- [AZD2693](https://sec-api.dev/pdufa/azd2693): Nonalcoholic Steatohepatitis
- [AZD3427](https://sec-api.dev/pdufa/azd3427): Pulmonary Hypertension (World Health Organization Group 2)
- [AZD4144](https://sec-api.dev/pdufa/azd4144): Sepsis
- [AZD4604](https://sec-api.dev/pdufa/azd4604): Asthma
- [AZD5004](https://sec-api.dev/pdufa/azd5004): Diabetes Mellitus, Type 2
- [AZD5148](https://sec-api.dev/pdufa/azd5148): Clostridioides Difficile Infection
- [AZD5335](https://sec-api.dev/pdufa/azd5335): Epithelial Ovarian Cancer
- [AZD5462](https://sec-api.dev/pdufa/azd5462): Chronic Heart Failure
- [AZD6234](https://sec-api.dev/pdufa/azd6234): Obesity, Obesity or Overweight, Endocrinology, Obesity/Overweight
- [AZD6793](https://sec-api.dev/pdufa/azd6793): Chronic Obstructive Pulmonary Disease (COPD)
- [AZD7798](https://sec-api.dev/pdufa/azd7798): Crohn's Disease, Moderate to Severe Crohn's Disease
- [AZD8630](https://sec-api.dev/pdufa/azd8630): Asthma
- [Azd8965 low dose](https://sec-api.dev/pdufa/azd8965): Idiopathic Pulmonary Fibrosis (IPF)
- [AZD9550](https://sec-api.dev/pdufa/azd9550): Obesity or Overweight
- [AZD9833](https://sec-api.dev/pdufa/azd9833): ER-Positive HER2-Negative Breast Cancer
- [Baxfendy (baxdrostat)](https://sec-api.dev/pdufa/baxdrostat): To treat hypertension in combination with other antihypertensive drugs, Uncontrolled Hypertension, Resistant Hypertension, Primary Hyperaldosteronism
- [Baxdrostat and dapagliflozin](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin): Heart Failure
- [Baxdrostat/dapagliflozin](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin): Chronic Kidney Disease and Hypertension
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi): Asthma
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160): Asthma
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab): Severe Eosinophilic Asthma, Hypereosinophilic Syndrome, Eosinophilic Asthma, Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi): Asthma
- [Bgf mdi 320/14.4/9.6 μg](https://sec-api.dev/pdufa/bgf-mdi-320-14-4): COPD (Chronic Obstructive Pulmonary Disease)
- [Bgf mdi hfo 320/14.4/9.6μg](https://sec-api.dev/pdufa/bgf-mdi-hfo-320-14-4): COPD (Chronic Obstructive Pulmonary Disease)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi): Asthma
- [Symbicort Aerosphere (budesonide; formoterol fumarate)](https://sec-api.dev/pdufa/budesonide-formoterol): Severe Asthma
- [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate)](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate): 
- [CAEL-101](https://sec-api.dev/pdufa/cael-101): AL Amyloidosis
- [Etcamah (camizestrant)](https://sec-api.dev/pdufa/camizestrant): ER-Positive HER2-Negative Breast Cancer, Breast Cancer, Early Breast Cancer, Advanced Breast Cancer
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib): To treat breast cancer that meets certain disease criteria, Breast Cancer, Locally Advanced (Inoperable) or Metastatic Breast Cancer, Prostate Cancer, Triple Negative Breast Neoplasms
- [Voydeya (danicopan)](https://sec-api.dev/pdufa/danicopan): To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria
- [Farxiga (dapagliflozin)](https://sec-api.dev/pdufa/dapagliflozin): Renal Insufficiency, Chronic, Type 2 Diabetes Mellitus, Chronic Kidney Disease With High Proteinuria
- [Xigduo Xr (dapagliflozin; metformin hydrochloride)](https://sec-api.dev/pdufa/dapagliflozin-metformin): 
- [Qternmet Xr (dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride)](https://sec-api.dev/pdufa/dapagliflozin-metformin-saxagliptin): 
- [Qtern (dapagliflozin; saxagliptin hydrochloride)](https://sec-api.dev/pdufa/dapagliflozin-saxagliptin): 
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd): Breast Cancer
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan): Non-small Cell Lung Cancer
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd): Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab): Non-Muscle- Invasive Bladder Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma, Small Cell Lung Carcinoma, Biliary Tract Cancer, Papillary Renal Cell Carcinoma
- [Durvalumab + chemotherapy phase](https://sec-api.dev/pdufa/durvalumab-chemotherapy-phase): Advanced or Recurrent Endometrial Cancer
- [Soliris (eculizumab)](https://sec-api.dev/pdufa/eculizumab): NMOSD, Atypical Hemolytic Uremic, Generalized Myasthenia Gravis (gMG)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron): Heart Failure With Preserved Ejection Fraction (HFpEF), Weight Management, Type 2 Diabetes Mellitus, Obesity, Chronic Kidney Disease
- [WAINUA (eplontersen)](https://sec-api.dev/pdufa/eplontersen): To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- [Byetta (exenatide synthetic)](https://sec-api.dev/pdufa/exenatide-synthetic): 
- [Bevespi Aerosphere (formoterol fumarate; glycopyrrolate)](https://sec-api.dev/pdufa/formoterol-glycopyrrolate): 
- [Faslodex (fulvestrant)](https://sec-api.dev/pdufa/fulvestrant): Locally Advanced or Metastatic Breast Cancer
- [Gefurulimab](https://sec-api.dev/pdufa/gefurulimab): Generalized Myasthenia Gravis
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi): Asthma
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi): Asthma
- [Laroprovstat](https://sec-api.dev/pdufa/laroprovstat): Hypercholesterolemia, Hypercholesterolaemia
- [Laroprovstat/rosuvastatin 1](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1): Hypercholesterolaemia
- [Lenbelintide](https://sec-api.dev/pdufa/lenbelintide): Obesity or Overweight
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib): Asthma
- [MEDI-546](https://sec-api.dev/pdufa/medi-546): Systemic Lupus Erythematosus
- [Kombiglyze Xr (metformin hydrochloride; saxagliptin hydrochloride)](https://sec-api.dev/pdufa/metformin-saxagliptin): 
- [NEXIUM-20MG](https://sec-api.dev/pdufa/nexium-20mg): Erosive Esophagitis
- [Nirsevimab](https://sec-api.dev/pdufa/nirsevimab): Lower Respiratory Tract Infection, Respiratory Syncytial Virus Infections
- [Beyfortus (nirsevimab-alip)](https://sec-api.dev/pdufa/nirsevimab-alip): To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release
- [LYNPARZA® (olaparib)](https://sec-api.dev/pdufa/olaparib): Ovarian Cancer, Advanced Solid Neoplasms
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib): Non-small Cell Lung Cancer, Stage II-IIIB Non-small Cell Lung Carcinoma, Cancer, Metastatic Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Carcinoma, Lung Cancer
- [Part a: zibotentan (dose b) + dapagliflozin](https://sec-api.dev/pdufa/part-a-zibotentan-dose-b-dapagliflozin): Liver Cirrhosis
- [Puxitatug samrotecan](https://sec-api.dev/pdufa/puxitatug-samrotecan): Endometrial Cancer
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab): Generalized Myasthenia Gravis, Delayed Graft Function, Thrombotic Microangiopathy, Paroxysmal Nocturnal Hemoglobinuria, Chronic Kidney Disease, NMOSD, Immunoglobulin A Nephropathy, Neuromyelitis Optica Spectrum Disorder
- [Ultomiris (ravulizumab-cwvz)](https://sec-api.dev/pdufa/ravulizumab-cwvz): 
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig): Carcinoma, Non-Small Cell Lung, Biliary Tract Cancer, HER2-positive Gastric Cancer, Non-Small Cell Lung Cancer
- [Saruparib](https://sec-api.dev/pdufa/saruparib): Metastatic Castration-Sensitive Prostate Cancer
- [Onglyza (saxagliptin hydrochloride)](https://sec-api.dev/pdufa/saxagliptin): 
- [Kanuma (sebelipase alfa)](https://sec-api.dev/pdufa/sebelipase-alfa): 
- [Koselugo (selumetinib sulfate)](https://sec-api.dev/pdufa/selumetinib): 
- [Koselugo (selumetinib; selumetinib sulfate)](https://sec-api.dev/pdufa/selumetinib-selumetinib): 
- [Sonesitatug vedotin](https://sec-api.dev/pdufa/sonesitatug-vedotin): Gastric Cancer, Gastroesophageal Adenocarcinoma
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig): Primary Membranous Nephropathy, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
- [Tarperprumig](https://sec-api.dev/pdufa/tarperprumig): Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab): severe chronic rhinosinusitis with nasal polyps, Chronic Rhinosinusitis With Nasal Polyps, Asthma, Severe Asthma, Chronic Obstructive Pulmonary Disease (COPD), Eosinophilic Esophagitis
- [Tezspire (tezepelumab-ekko)](https://sec-api.dev/pdufa/tezepelumab-ekko): 
- [Brilinta (ticagrelor)](https://sec-api.dev/pdufa/ticagrelor): 
- [Torvutatug samrotecan](https://sec-api.dev/pdufa/torvutatug-samrotecan): Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Epithelial Ovarian Cancer
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab): Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- [Tozorakimab 1](https://sec-api.dev/pdufa/tozorakimab-1): Chronic Obstructive Pulmonary Disease (COPD)
- [Tozorakimab dose regimen 1](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1): Chronic Obstructive Pulmonary Disease
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan): unresectable, advanced or metastatic her2-expressing solid tumors, Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Breast Cancer; HER2-positive; Metastatic, Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer), Endometrial Cancer
- [Treatment a : budesonide, glycopyrronium, and formoterol fumarate](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol): Chronic Obstructive Pulmonary Disease
- [Tremelimumab](https://sec-api.dev/pdufa/tremelimumab): Hepatocellular Carcinoma
- [Imjudo (tremelimumab-actl)](https://sec-api.dev/pdufa/tremelimumab-actl): To treat unresectable hepatocellular carcinoma
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig): Metastatic Colorectal Cancer, Locally Advanced Cervical Cancer, Unresectable Pleural Mesothelioma, Hepatocellular Carcinoma, Metastatic Non-small Cell Lung Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Non-small Cell Lung Cancer
- [Xofigo](https://sec-api.dev/pdufa/xofigo): Metastatic Castration-resistant Prostate Cancer
- [Lokelma (sodium zirconium cyclosilicate)](https://sec-api.dev/pdufa/zirconium-cyclosilicate): 
- [Sodium zirconium cyclosilicate (szc) reduced dose level](https://sec-api.dev/pdufa/zirconium-cyclosilicate-szc-reduced): Hyperkalaemia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/azn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AZN catalysts: ASTRAZENECA PLC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/azn/catalysts

```bibtex
@misc{secapidev_companies_azn_catalysts_20261116,
  title        = {AZN catalysts: ASTRAZENECA PLC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/azn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_azn_catalysts_20261116","title":"AZN catalysts: ASTRAZENECA PLC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/azn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
